enGene Therapeutics Inc. ENGN
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.92M | 9.77M | 8.93M | 7.76M | 7.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.01M | 31.97M | 31.19M | 39.48M | 29.95M |
| Operating Income | -34.01M | -31.97M | -31.19M | -39.48M | -29.95M |
| Income Before Tax | -32.50M | -30.23M | -29.75M | -38.38M | -28.75M |
| Income Tax Expenses | -- | -- | -- | -497.00K | 239.00K |
| Earnings from Continuing Operations | -32.50M | -30.23M | -29.75M | -37.88M | -28.99M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.50M | -30.23M | -29.75M | -37.88M | -28.99M |
| EBIT | -34.01M | -31.97M | -31.19M | -39.48M | -29.95M |
| EBITDA | -33.84M | -31.79M | -31.00M | -39.31M | -29.82M |
| EPS Basic | -0.47 | -0.43 | -0.44 | -0.74 | -0.57 |
| Normalized Basic EPS | -0.29 | -0.27 | -0.27 | -0.47 | -0.35 |
| EPS Diluted | -0.47 | -0.43 | -0.44 | -0.74 | -0.57 |
| Normalized Diluted EPS | -0.29 | -0.27 | -0.27 | -0.47 | -0.35 |
| Average Basic Shares Outstanding | 69.73M | 69.72M | 67.26M | 51.38M | 51.10M |
| Average Diluted Shares Outstanding | 69.73M | 69.72M | 67.26M | 51.38M | 51.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |